Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Connick

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Multiple Sclerosis and Related Disorders|May 16, 2022
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosisStella A Glasmacher, Patrick Ka Kearns, Zackary Hassan, et al.
Plos One|May 27, 2020
Systematic review of prediction models in relapsing remitting multiple sclerosisFraser S Brown, Stella A Glasmacher, Patrick K A Kearns, et al.
Multiple Sclerosis and Related Disorders|June 7, 2022
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trialPeter Foley, Richard A Parker, Floriana de Angelis, et al.
The Lancet. Neurology|May 30, 2020
MS-SMART study: systematic sampling bias concerns - Authors' replyJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
BMJ Open Ophthalmology|September 26, 2022
Longitudinal retinal imaging study of newly diagnosed relapsing-remitting multiple sclerosis in Scottish population: baseline and 12 months follow-up profile of FutureMS retinal imaging cohortYingdi Chen, Juan Larraz, Michael Wong, et al.
Ebiomedicine|February 13, 2016
Hypothermic Preconditioning Reverses Tau Ontogenesis in Human Cortical Neurons and is Mimicked by Protein Phosphatase 2A InhibitionNina M Rzechorzek, Peter Connick, Matthew R Livesey, et al.
Plos One|April 10, 2015
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosisHanna M Vesterinen, Peter Connick, Cadi M J Irvine, et al.
Brain Communications|December 8, 2021
MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosisElizabeth N York, Sarah-Jane Martin, Rozanna Meijboom, et al.
Plos One|July 28, 2023
Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosisRozanna Meijboom, Elizabeth N York, Agniete Kampaite, et al.
The Lancet. Neurology|January 13, 2012
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Madhan Kolappan, Charles Crawley, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis and Related Disorders|May 16, 2022
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosisStella A Glasmacher, Patrick Ka Kearns, Zackary Hassan, et al.
Plos One|May 27, 2020
Systematic review of prediction models in relapsing remitting multiple sclerosisFraser S Brown, Stella A Glasmacher, Patrick K A Kearns, et al.
Multiple Sclerosis and Related Disorders|June 7, 2022
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trialPeter Foley, Richard A Parker, Floriana de Angelis, et al.
The Lancet. Neurology|May 30, 2020
MS-SMART study: systematic sampling bias concerns - Authors' replyJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
BMJ Open Ophthalmology|September 26, 2022
Longitudinal retinal imaging study of newly diagnosed relapsing-remitting multiple sclerosis in Scottish population: baseline and 12 months follow-up profile of FutureMS retinal imaging cohortYingdi Chen, Juan Larraz, Michael Wong, et al.
Ebiomedicine|February 13, 2016
Hypothermic Preconditioning Reverses Tau Ontogenesis in Human Cortical Neurons and is Mimicked by Protein Phosphatase 2A InhibitionNina M Rzechorzek, Peter Connick, Matthew R Livesey, et al.
Plos One|April 10, 2015
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosisHanna M Vesterinen, Peter Connick, Cadi M J Irvine, et al.
Brain Communications|December 8, 2021
MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosisElizabeth N York, Sarah-Jane Martin, Rozanna Meijboom, et al.
Plos One|July 28, 2023
Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosisRozanna Meijboom, Elizabeth N York, Agniete Kampaite, et al.
The Lancet. Neurology|January 13, 2012
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Madhan Kolappan, Charles Crawley, et al.
Pageof 4